About MG Partners

• Founded: 2000

• Headquarters: Houten, Netherlands

• Strategy: Healthcare buy-and-build, Benelux

• Thesis: Building market-leading healthcare businesses through operational consolidation and professionalization of founder-owned companies in the Benelux region

• Track record: Fund VI raised €50m in 2020; previous funds typically range €30m–€50m

• Leadership: Founded by Martijn Groenleer

MG Partners closed Fund VII at €80m hard cap after an oversubscribed raise, marking a 60% step-up from its €50m predecessor fund. The vehicle targets the firm's established healthcare buy-and-build strategy across the Benelux region, where consolidation opportunities remain concentrated in founder-owned businesses across sub-sectors like primary care, diagnostics, and allied health services.

The oversubscription and fund-size increase arrive as healthcare-focused PE in Europe faces mixed LP appetite. Valuations in healthcare services have compressed roughly 15–20% from 2021 peaks, creating entry-point opportunities for smaller regional funds. MG Partners' track record in Benelux healthcare — a market with fragmented ownership structures and limited institutional buyer competition below €50m enterprise value — positions the fund to deploy capital in environments where larger pan-European healthcare funds face valuation discipline.

The 60% jump from Fund VI creates a deployment question worth tracking: whether the firm scales portfolio company count or check sizes. MG Partners historically builds 3–4 platforms per fund, adding bolt-ons over 4–5 year hold periods. An €80m fund at that cadence implies larger platform acquisitions or faster bolt-on velocity. If the firm maintains its historical company count, average equity checks rise to €15m–€20m per platform — pushing into lower mid-market territory where buyer competition from both regional and international funds intensifies.

Source: AltAssets